Smith & Nephew Past Earnings Performance

Past criteria checks 3/6

Smith & Nephew's earnings have been declining at an average annual rate of -18.9%, while the Medical Equipment industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 2.4% per year. Smith & Nephew's return on equity is 5%, and it has net margins of 4.7%.

Key information

-18.9%

Earnings growth rate

-19.0%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate2.4%
Return on equity5.0%
Net Margin4.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Smith & Nephew: Orthopedics Growth Continues To Drive Sales Forward

Dec 28

Smith & Nephew Getting More Interesting As A Contrarian Idea

Oct 12

Smith & Nephew: Entering New Markets But Growth Is Slow Still

Aug 01

Smith & Nephew reports FY earnings; initiates FY23 guidance

Feb 21

Smith & Nephew: Potential Only Has Value If You Can Execute

Dec 14

Smith & Nephew: Still A Buy Despite Short-Term Challenges

Sep 26

Smith & Nephew 1H 2022 Earnings Preview

Jul 27

Smith+Nephew launches app Wound Compass to help reduce variation in wound care

Jul 12

Smith & Nephew: Fair Price For An Attractive Medical Devices Supplier

Jun 01

Smith & Nephew: Valuation Looking More Attractive

Jan 26

Smith & Nephew Is A Premium Brand That Should Deliver Something Special

Nov 06

Smith & Nephew Leveraged To Post-Pandemic Normalization And Self-Help

Sep 02

Smith & Nephew plc: Improving Performance Reflected In Price

Jun 18

Smith & Nephew: Pandemic Long Tail Reduces Attractiveness

Jan 14

Smith & Nephew: A Long-Term Buy And Hold In Medical Devices

Nov 09

Revenue & Expenses Breakdown
Beta

How Smith & Nephew makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSE:SNN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 235,5492632,890320
30 Sep 235,4492412,816324
01 Jul 235,3492182,741327
01 Apr 235,2822212,718331
31 Dec 225,2152232,695335
30 Sep 225,2143602,680344
02 Jul 225,2134962,665352
02 Apr 225,2135102,651351
31 Dec 215,2125242,637349
30 Sep 215,1685392,607340
03 Jul 215,1245532,576330
03 Apr 214,8425012,508319
31 Dec 204,5604482,439307
30 Sep 204,6244202,470304
27 Jun 204,6883912,501301
27 Mar 204,9134962,518297
31 Dec 195,1386002,534292
30 Sep 195,0446492,449281
29 Jun 194,9496982,364269
29 Mar 194,9276812,374258
31 Dec 184,9046632,384246
30 Sep 184,8876902,450239
30 Jun 184,8697172,496232
31 Mar 184,8177422,453228
31 Dec 174,7657672,419223
30 Sep 174,7218172,346224
01 Jul 174,6778672,282224
01 Apr 174,6738262,269227
31 Dec 164,6697842,255230
30 Sep 164,6805702,515228
02 Jul 164,6903562,393225
02 Apr 164,6623832,363224
31 Dec 154,6344102,524222
30 Sep 154,7025132,333224
27 Jun 154,6695572,326225
27 Mar 154,6804992,375234
31 Dec 144,6175012,323235
27 Sep 144,5435032,285239
28 Jun 144,4225232,201241
29 Mar 144,3495632,124235
31 Dec 134,3515562,149231
28 Sep 134,2535342,045215
29 Jun 134,1785442,013196

Quality Earnings: SNN has a large one-off loss of $264.0M impacting its last 12 months of financial results to 31st December, 2023.

Growing Profit Margin: SNN's current net profit margins (4.7%) are higher than last year (4.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SNN's earnings have declined by 18.9% per year over the past 5 years.

Accelerating Growth: SNN's earnings growth over the past year (17.9%) exceeds its 5-year average (-18.9% per year).

Earnings vs Industry: SNN earnings growth over the past year (17.9%) exceeded the Medical Equipment industry 6.3%.


Return on Equity

High ROE: SNN's Return on Equity (5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.